La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Century Therapeutics Dividende

Dividende contrôle des critères 0/6

Century Therapeutics n'a pas d'antécédents de versement de dividendes.

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	2.0%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-US$1.55
Prévisions de rendement du dividende à 3 ans	0%

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Jun 20

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Mar 06

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Feb 01

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Oct 23

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Aug 25

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de IPSC ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de IPSC ont augmenté.

Rendement des dividendes par rapport au marché

Century Therapeutics Rendement des dividendes par rapport au marché

Comment le rendement du dividende de IPSC se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (IPSC)	n/a
25% du marché (US)	1.4%
25% du marché (US)	4.3%
Moyenne du secteur (Biotechs)	2.0%
Prévisions des analystes dans 3 ans (IPSC)	0%

Dividende notable: Impossible d'évaluer le rendement des dividendes de IPSC par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Dividende élevé: Impossible d'évaluer le rendement des dividendes de IPSC par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.

Bénéfice distribué aux actionnaires

Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de IPSC afin de déterminer si ses paiements de dividendes sont couverts par les bénéfices.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car IPSC n'a signalé aucun versement.

Century Therapeutics Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

Price target decreased by 7.1% to US$11.33

Consensus revenue estimates increase by 24%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Century Therapeutics Presents Interim Results from Phase 1 Elipse-1 Study At Asco 2024 Annual Meeting

Price target decreased by 18% to US$12.20

Consensus revenue estimates increase by 77%

Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.53 loss in 1Q 2023)

Century Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors

Century Therapeutics, Inc. (NasdaqGS:IPSC) agreed to acquire Clade Therapeutics, Inc. from Syncona Limited (LSE:SYNC) for $45 million.

Consensus revenue estimates decrease by 86%, EPS upgraded

Full year 2023 earnings released: US$2.30 loss per share (vs US$2.27 loss in FY 2022)

COO & Head of Early Development notifies of intention to sell stock

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for A Multi-Dosing Strategy for Car iNK Enabled by Allo-Evasion Edits

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

New minor risk - Share price stability

Consensus revenue estimates fall by 32%

Century Therapeutics, Inc. Announces Chief Executive Officer Changes

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

New major risk - Financial position

New minor risk - Market cap size

Consensus revenue estimates increase by 20%

Price target decreased by 19% to US$14.00

Consensus revenue estimates decrease by 48%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Financial position

Price target decreased by 9.2% to US$17.89

Price target decreased by 8.6% to US$18.00

Chief Scientific Officer recently sold US$55k worth of stock

Chief Scientific Officer exercised options and sold US$351k worth of stock

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Elipse-1 Trial Evaluating Cnty-101 in Relapsed or Refractory Cd19 Positive B-Cell Lymphomas

Price target decreased to US$20.30

Consensus revenue estimates increase by 26%

High number of new and inexperienced directors

Century Therapeutics Announces Presentation of Preclinical Data At the SITC 37Th Annual Meeting and Provides Pipeline Updates

Price target decreased to US$22.44

Casdin Capital Engages in Discussions with Century Therapeutics

Century Therapeutics, Inc. Announces Board Changes

Century Therapeutics, Inc. Receives Study May Proceed Notification from FDA for CNTY-101

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Consensus revenue estimates fall by 20%

Century Therapeutics, Inc.(NasdaqGS:IPSC) dropped from Russell 2000 Growth Index

Consensus revenue estimates increase by 2,133%

High number of new and inexperienced directors

Century Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

High number of new and inexperienced directors

Century Therapeutics Announces Presentation of Data At the 63Rd American Society of Hematology Annual Meeting and Provides Pipeline Updates

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés